AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke AXIOMATIC-SSP: Cautious Optimism on Factor XI Inhibitor in Stroke

The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic stroke or TIA, on top of dual antiplatelet therapy.Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Cardiology News Source Type: news